Skip to main content
. Author manuscript; available in PMC: 2009 Oct 2.
Published in final edited form as: Gynecol Oncol. 2005 Jan;96(1):32–41. doi: 10.1016/j.ygyno.2004.09.057

Fig. 2.

Fig. 2

Immunoprecipitation and immunoblot recognition of PR by antibodies purported to recognize both PRA and PRB. (A) The antibody AB52 was used to IP extracts containing no PR (lanes 1 and 2), PRA (lanes 3 and 4), and PRB (lanes 5 and 6). Progesterone or vehicle alone was added to the media as indicated. Lanes 7-13 demonstrate the companion immunoblot indicating the presence of PR isoforms in the extracts prior to IP. (B) The Dako PR antibody was used to IP the extracts as indicated (lanes 1-6), and the immunoblot (lanes 7-12) confirms the presence of PRA (lanes 9 and 10) and PRB (lanes 11 and 12) prior to IP. (C) The Ventana PR antibody was used to IP extracts (lanes 1-6) containing no PR, PRA, or PRB as indicated. The companion immunoblot (lanes 7-12) confirms the presence of PRA and PRB prior to IP. For all immunoblots, AB52 was used to recognize PRA and PRB.